Effect of Lanabecestat on the Pharmacokinetics of Ethinyl Estradiol and Levonorgestrel in Healthy Female Subjects

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 04 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lanabecestat (Primary) ; Ethinylestradiol/levonorgestrel
Indications Alzheimer's disease
Focus Pharmacokinetics
Sponsors Eli Lilly and Company

Most Recent Events

26 Jun 2018 Planned End Date changed from 19 Oct 2018 to 1 Oct 2018.
26 Jun 2018 Planned primary completion date changed from 19 Oct 2018 to 1 Oct 2018.
26 Jun 2018 Planned initiation date changed from 14 Jun 2018 to 1 Jun 2018.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight